All News

A longer treatment-free survival was seen in patients with advanced renal cell carcinoma who were treated with first-line nivolumab and ipilimumab compared with sunitinib.

An interim analysis demonstrated positive efficacy and safety in patients with metastatic solid tumors who were treated with etigilimab plus nivolumab.

Susan M. O’Brien, MD, on potential upcoming approvals in 2022 for treating chronic lymphocytic leukemia with combination therapies.

Nina Shah, MD, looks to the future of treating patients with multiple myeloma.

At ASH 2021, CancerNetwork® spoke with Ruben Mesa, MD, of UT Health San Antonio MD Anderson Cancer Center, about which presentation from the conference could be practice changing for patients with myelofibrosis.

Amy Comander, MD, shares her thoughts on key developments in breast cancer care that took place in 2021, and reflects on what the future might hold for this patient population

Susan M. O’Brien, MD, on upcoming 2022 trends in chronic lymphocytic leukemia treatment.

Nina Shah, MD, discusses maintenance therapies in emerging clinical trials for multiple myeloma.

Patients who have been diagnosed with acute graft-versus-host disease with high levels of amphiregulin could be at a higher risk for early mortality.

Cervical cancer incidence rates were significantly higher in the lowest-socioeconomic status neighborhoods vs the highest-socioeconomic status neighborhoods in New York City.

Susan M. O’Brien, MD, on why clinical trial enrollment is so important for patients with chronic lymphocytic leukemia.

Luciano Costa, MD, PhD, spoke about the potential application of daratumumab, carfilzomib, lenalidomide, and dexamethasone for multiple myeloma in a real-world setting.

Black and Hispanic patients continue to be notably underrepresented in clinical cancer research, although research noted that participation is on the rise.

Prognostic awareness impacted patients quality of life through psychosocial distress and symptoms burden.

At ASH 2021, CancerNetwork® spoke with Ruben Mesa, MD, of UT Health San Antonio MD Anderson Cancer Center, about FDA approvals for myelofibrosis that may impact the standard of care.

Nina Shah, MD, discusses some of the important phase 3 trials to emerge from the previous year in multiple myeloma.

Nina Shah, MD, touched on novel immunotherapies and other emerging therapies for patients with multiple myeloma.

Using the International Prognostic Scoring System (IPSS) score and JAK2 mutation status, thrombosis risk could potentially be identified for patients with primary myelofibrosis.

A cohort study did not identify strong associations between outpatient or inpatient neutropenia management and increased bacteremia incidence, treatment delays, or worse health-related quality of life for pediatric patients with acute myeloid leukemia.

A non inferiority design was presented at ASH 2021 for acalabrutinib plus venetoclax in treatment-naive chronic lymphocytic leukemia or small lymphocytic leukemia.

Susan M. O’Brien, MD, highlights ongoing trials from 2021 examining combination therapies for patients with chronic lymphocytic leukemia.

Matthew S. Davids, MD, spoke about which abstracts presented at ASH 2021 he felt were most important.

Nina Shah, MD, details the process to choose optimal therapeutic options for patients with relapsed/refractory multiple myeloma.

Nina Shah, MD, on BCMA-directed treatments for patients with multiple myeloma.

Susan M. O’Brien, MD, discusses novel mechanisms of action and BTK inhibitors for patients with chronic lymphocytic leukemia.

Mehmet Sitki Copur, MD, gives his perspective on liquid biopsies and how they can be utilized in gastrointestinal cancer.

Nina Shah, MD, discussed how adverse events impact treatment decision-making for patients with multiple myeloma.

Patient data from 4 clinical trials suggests HER2-low–positive tumors can be seen as a new breast cancer subgroup, specifically distinct from HER2-zero tumors.

Phase 3 data indicated that primary tumor resection followed by systemic treatment produced higher 60-day mortality vs systemic treatment alone for patients with metastatic colorectal cancer.

Early relapsed appears to be an important predictor of survival among patients with mantle cell lymphoma.